 This is a prospective, multicenter, single arm, non-randomized phase 2 study in up to 20 adult patients with limb-threatening damage to the superficial femoral or popliteal artery who require surgical repair. Subjects will be implanted with a Humacyte Human Acellular Vessel HAV as an interposition vessel or bypass using standard vascular surgical techniques. There is no control arm. 